MedTrace Logo

A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium

NCT03097003 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2020-04-27

No results posted yet for this study

Summary

OTELO is a national (Belgium), multicentre, prospective, non-interventional, post-marketing study. The study will include a representative sample of approximately 250 patients with moderate-to-severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label and reimbursement criteria. Patients may be enrolled into the study up to 4 weeks after commencing the study treatment.

As this study is non-interventional, drug dosing and treatment duration will be at the sole discretion of the treating dermatologist, in accordance with the local label and daily clinical practice.

Conditions

Interventions

DRUG

Apremilast

Psoriasis patients treated with Otezla® (Apremilast) in Belgium

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-06
Primary Completion
2018-12-20
Completion
2018-12-20

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03097003 on ClinicalTrials.gov